| abstract |
Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine are disclosed for use in the treatment of cancer, especially in the treatment of cancers in which patients show resistance, for example, in cells with reduced levels of nucleoside transporters and/or in patients with nucleoside kinase-deficient cells and/or with mycoplasma-infected cells and/or cells with elevated levels of thymidylate synthase. |